Dr. Jeffrey Engelman is an Associate Professor of Medicine at Harvard Medical School and is the Director of Thoracic Oncology and Director of Molecular Therapeutics at Massachusetts General Hospital.
He received his Bachelor of Arts in Chemistry from Northwestern University and his MD and PhD degrees from the Albert Einstein College of Medicine. Dr. Engelman completed his medical residency in Internal Medicine at Brigham and Women’s Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program. He joined the Harvard Medical School faculty and Massachusetts General Hospital in 2005.
Dr. Engelman is also the PI of his own laboratory at the MGH Cancer Center. The overarching aim of his research is to develop new and more potent therapeutic strategies for the treatment of cancer, with a particular emphasis on lung cancer. Many of his laboratory findings have shaped the current landscape of targeted therapies and ongoing clinical trials.
In his role as the Director of Thoracic Oncology at MGH, he directs the research program of the thoracic oncology team. This program integrates laboratory studies, clinical trials, and comprehensive molecular analyses of cancers to pioneer individualized therapies. This includes a program of repeat biopsies Dr. Engelman has instituted for patients with acquired resistance to targeted therapies. These tumors are collected for comprehensive genetic and proteomic analyses used to develop more laboratory models for discovery, a mission central to the MGH Cancer Center.